よむ、つかう、まなぶ。
【参考資料6】抗微生物薬適正使用の手引き 第三版 補遺 (41 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_45318.html |
| 出典情報 | 厚生科学審議会 感染症部会 薬剤耐性（AMR）に関する小委員会 抗微生物薬適正使用（AMS）等に関する作業部会（第6回 11／19）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
139. Brooke JS. Advances in the Microbiology of Stenotrophomonas maltophilia. Clin Microbiol
Rev. 2021 Jun;34(3):e0003019.
140. Garcia-Leon G, Ruiz de Alegria Puig C, Garcia de la Fuente C, Martinez-Martinez L,
Martinez JL, Sanchez MB. High-level quinolone resistance is associated with the
overexpression of smeVWX in Stenotrophomonas maltophilia clinical isolates. Clin Microbiol
Infect. 2015 May;21(5):464-467.
141. Garcia-Leon G, Salgado F, Oliveros JC, Sanchez MB, Martinez JL. Interplay between
intrinsic and acquired resistance to quinolones in Stenotrophomonas maltophilia. Environ
Microbiol. 2014 May;16(5):1282-1296.
142. Toleman MA, Bennett PM, Bennett DM, Jones RN, Walsh TR. Global emergence of
trimethoprim/sulfamethoxazole resistance in Stenotrophomonas maltophilia mediated by
acquisition of sul genes. Emerg Infect Dis. 2007 Apr;13(4):559-65.
143. Hu LF, Chang X, Ye Y. et al. Stenotrophomonas maltophilia resistance to
trimethoprim/sulfamethoxazole mediated by acquisition of sul and dfrA genes in a plasmidmediated class 1 integron. Int J Antimicrob Agents. 2011 Mar;37(3):230-234.
144. Khan A, Pettaway C, Dien Bard J, Arias CA, Bhatti MM, Humphries RM. Evaluation of the
Performance of Manual Antimicrobial Susceptibility Testing Methods and Disk Breakpoints for
Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 2023 May;95(5):e02631-20.
145. Khan A, Arias CA, Abbott A, Dien Bard J, Bhatti MM, Humphries RM. Evaluation of the Vitek
2, Phoenix, and MicroScan for Antimicrobial Susceptibility Testing of Stenotrophomonas
maltophilia. J Clin Microbiol. 2021 Aug;59(9):e0065421.
146. Mojica MF, Humphries R, Lipuma JJ. et al. Clinical challenges treating Stenotrophomonas
maltophilia infections: an update. JAC Antimicrob Resist. 2022 May;4(3):dlac040.
147. Cho SY, Kang CI, Kim J. et al. Can levofloxacin be a useful alternative to trimethoprimsulfamethoxazole for treating Stenotrophomonas maltophilia bacteremia? Antimicrob Agents
Chemother. 2014;58(1):581-583.
148. Ko JH, Kang CI, Cornejo-Juarez P. et al. Fluoroquinolones versus trimethoprimsulfamethoxazole for the treatment of Stenotrophomonas maltophilia infections: a systematic
review and meta-analysis. Clin Microbiol Infect. 2019 May;25(5):546-554.
149. Sarzynski SH, Warner S, Sun J. et al. Trimethoprim-Sulfamethoxazole Versus Levofloxacin
for Stenotrophomonas maltophilia Infections: A Retrospective Comparative Effectiveness
Study of Electronic Health Records from 154 US Hospitals. Open Forum Infect Dis. 2022
Jan;9(2):ofab644.
150. Biagi M, Tan X, Wu T. et al. Activity of Potential Alternative Treatment Agents for
Stenotrophomonas maltophilia Isolates Nonsusceptible to Levofloxacin and/or TrimethoprimSulfamethoxazole. J Clin Microbiol. 2020 Jan;58(2):e01603-19.
151. Flamm RK, Shortridge D, Castanheira M, Sader HS, Pfaller MA. In Vitro Activity of
Minocycline against U.S. Isolates of Acinetobacter baumannii-Acinetobacter calcoaceticus
Species Complex, Stenotrophomonas maltophilia, and Burkholderia cepacia Complex:
Results from the SENTRY Antimicrobial Surveillance Program, 2014 to 2018. Antimicrob
Agents Chemother. 2019 Oct;63(11):e01154-19.
41
Rev. 2021 Jun;34(3):e0003019.
140. Garcia-Leon G, Ruiz de Alegria Puig C, Garcia de la Fuente C, Martinez-Martinez L,
Martinez JL, Sanchez MB. High-level quinolone resistance is associated with the
overexpression of smeVWX in Stenotrophomonas maltophilia clinical isolates. Clin Microbiol
Infect. 2015 May;21(5):464-467.
141. Garcia-Leon G, Salgado F, Oliveros JC, Sanchez MB, Martinez JL. Interplay between
intrinsic and acquired resistance to quinolones in Stenotrophomonas maltophilia. Environ
Microbiol. 2014 May;16(5):1282-1296.
142. Toleman MA, Bennett PM, Bennett DM, Jones RN, Walsh TR. Global emergence of
trimethoprim/sulfamethoxazole resistance in Stenotrophomonas maltophilia mediated by
acquisition of sul genes. Emerg Infect Dis. 2007 Apr;13(4):559-65.
143. Hu LF, Chang X, Ye Y. et al. Stenotrophomonas maltophilia resistance to
trimethoprim/sulfamethoxazole mediated by acquisition of sul and dfrA genes in a plasmidmediated class 1 integron. Int J Antimicrob Agents. 2011 Mar;37(3):230-234.
144. Khan A, Pettaway C, Dien Bard J, Arias CA, Bhatti MM, Humphries RM. Evaluation of the
Performance of Manual Antimicrobial Susceptibility Testing Methods and Disk Breakpoints for
Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 2023 May;95(5):e02631-20.
145. Khan A, Arias CA, Abbott A, Dien Bard J, Bhatti MM, Humphries RM. Evaluation of the Vitek
2, Phoenix, and MicroScan for Antimicrobial Susceptibility Testing of Stenotrophomonas
maltophilia. J Clin Microbiol. 2021 Aug;59(9):e0065421.
146. Mojica MF, Humphries R, Lipuma JJ. et al. Clinical challenges treating Stenotrophomonas
maltophilia infections: an update. JAC Antimicrob Resist. 2022 May;4(3):dlac040.
147. Cho SY, Kang CI, Kim J. et al. Can levofloxacin be a useful alternative to trimethoprimsulfamethoxazole for treating Stenotrophomonas maltophilia bacteremia? Antimicrob Agents
Chemother. 2014;58(1):581-583.
148. Ko JH, Kang CI, Cornejo-Juarez P. et al. Fluoroquinolones versus trimethoprimsulfamethoxazole for the treatment of Stenotrophomonas maltophilia infections: a systematic
review and meta-analysis. Clin Microbiol Infect. 2019 May;25(5):546-554.
149. Sarzynski SH, Warner S, Sun J. et al. Trimethoprim-Sulfamethoxazole Versus Levofloxacin
for Stenotrophomonas maltophilia Infections: A Retrospective Comparative Effectiveness
Study of Electronic Health Records from 154 US Hospitals. Open Forum Infect Dis. 2022
Jan;9(2):ofab644.
150. Biagi M, Tan X, Wu T. et al. Activity of Potential Alternative Treatment Agents for
Stenotrophomonas maltophilia Isolates Nonsusceptible to Levofloxacin and/or TrimethoprimSulfamethoxazole. J Clin Microbiol. 2020 Jan;58(2):e01603-19.
151. Flamm RK, Shortridge D, Castanheira M, Sader HS, Pfaller MA. In Vitro Activity of
Minocycline against U.S. Isolates of Acinetobacter baumannii-Acinetobacter calcoaceticus
Species Complex, Stenotrophomonas maltophilia, and Burkholderia cepacia Complex:
Results from the SENTRY Antimicrobial Surveillance Program, 2014 to 2018. Antimicrob
Agents Chemother. 2019 Oct;63(11):e01154-19.
41